Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet.

Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

The stock's fall snapped a three-day winning streak.

Korea has developed the world's first recombinant protein-based anthrax vaccine, a major step toward self-sufficiency that ...

The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...